Clinical Trial Detail

NCT ID NCT02055820
Title A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

diffuse large B-cell lymphoma

non-Hodgkin lymphoma

Therapies

Venetoclax

Rituximab

Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate

Obinutuzumab

Age Groups: adult

No variant requirements are available.